Know Cancer

forgot password

A Phase I Study of RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer

Phase 1
18 Years
Open (Enrolling)
HEAD & NECK Cancer

Thank you

Trial Information

A Phase I Study of RAD001 (Everolimus) + Docetaxel + Cisplatin as Induction Chemotherapy in Patients With Local-Regional Advanced Head and Neck Cancer

Inclusion Criteria:

- Stage III-IVB head and neck squamous cell carcinoma (HNSCC) or nasopharyngeal cancer
(WHO type I, II or III),, previously untreated. Patients with stage II hypopharynx
HNSCC will also be eligible. Pathology must be confirmed at MSKCC

- Age ≥ 18 years

- Karnofsky performance status ≥ 70%

- Adequate bone marrow function: Absolute neutrophil count ≥ 1.5 X 109/L, Platelets ≥
100 x 109/L, Hemoglobin > 10 g/dL.

- Adequate liver function Serum bilirubin must be within the upper limit of normal.
(ULN). AST and ALT and Alkaline Phosphatase must be within the range allowing for

- Adequate renal function: serum creatinine within institutional normal limits, or
calculated creatinine clearance (by Cockcroft and Gault method) ≥ 55 mL/min for
patients with creatinine limits above institutional normal

- INR < 1.5 or aPTT < 1.5 X upper limits of normal

- Negative urine or serum pregnancy test within 14 days prior to administration of

- Men and women of childbearing potential must be willing to consent to using effective
contraception while on treatment and for at least 3 months thereafter.

- Patients must have ability to understand and the willingness to sign a written
informed consent document

Exclusion Criteria:

- Any prior treatment with RAD001, or other agents specifically targeting mTOR

- Any prior radiation therapy for head and neck cancer. Any prior radiation therapy to
>25% of the bone marrow. Any prior radiation to whole pelvis and/or brain

- Therapeutic anticoagulation with coumadin (warfarin)

- Hypertriglyceridemia ≥ grade 2 (CTCAE version 3.0)

- Patients who require chronic treatment with steroids ( > prednisone 5 mg/day) or
other immunosuppressive agents are excluded. Both cisplatin and RAD001 are
immunosuppressive, and chronic steroid use (> prednisone 5 mg/day) or use of other
immunosuppressive agents might increase the risk of lethal infection in this setting.
Patients on low- dose steroid replacement regimens (≤ prednisone 5 mg/day) are not
excluded, because low dose steroids should not be immunosuppressive

- Impairment of gastrointestinal function or gastrointestinal disease that may
significantly alter the absorption of RAD001 (e.g., ulcerative disease, uncontrolled
nausea, vomiting, diarrhea, malabsorption syndrome or small bowel resection)

- Active infection or serious underlying medical condition that would impair the
patient's ability to receive protocol treatment. Other concurrent severe and/or
uncontrolled medical disease which would compromise participation in the study in the
opinion of the investigator (e.g., uncontrolled diabetes, unstable angina, or
congestive heart failure - New York Heart Association Class III or IV)

- HIV-positive patients. These patients are at increased risk of lethal infections
when treated with marrow suppressive therapy. Additionally, pharmacokinetic
interactions between antiretroviral therapy and the study regimen may be problematic
for these patients

- Women who are pregnant or lactating

- Other active malignancy, other than indolent malignancies which the investigator
determines are unlikely to interfere with treatment and safety analysis. For example,
patients with non-melanoma skin cancer, in situ carcinoma of the cervix, or prostate
cancer with no current biochemical (PSA) or radiologic evidence of disease may enroll

- Patients with hearing loss requiring hearing aid or intervention (i.e. interfering in
a clinical significant way with activities of daily living).

- Patients with multifocal peripheral sensory alterations or paresthesias (including
tingling) interfering with function, per patient report (example: activities of daily

- Impaired lung function: O2 saturation 88% or less at rest on room air by Pulse
Oximetry. If O2 saturation is ≤ 88% at rest, further pulmonary function tests (PFTs)
should be ordered to confirm normal pulmonary function and eligibility

- Patients should not receive immunization with attenuated live vaccines within one
week of study entry or during the study period. Close contact with those who have
received attenuated live vaccines should be avoided during treatment with everolimus.
Examples of live vaccines include intranasal influenza, measles, mumps, rubella, oral
polio, BCG, yellow fever, varicella, and TY21a typhoid vaccines

- Liver disease such as cirrhosis or severe hepatic impairment (Childs-Pugh class C)

Type of Study:


Study Design:

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

To determine the phase II recommended dose of RAD001 (everolimus) + docetaxel + cisplatin as induction chemotherapy for patients with head and neck cancer

Outcome Time Frame:

2 years

Safety Issue:


Principal Investigator

Matthew Fury, MD PhD

Investigator Role:

Principal Investigator

Investigator Affiliation:

Memorial Sloan-Kettering Cancer Center


United States: Food and Drug Administration

Study ID:




Start Date:

July 2009

Completion Date:

July 2013

Related Keywords:

  • Head & Neck Cancer
  • RAD001
  • 09-028
  • Squamous Cell Carcinoma
  • Local-Regional Advanced Head and Neck
  • Head and Neck Neoplasms



Memorial Sloan-Kettering Cancer CenterNew York, New York  10021
Memorial Sloan-Kettering Cancer Center at Basking RidgeBasking Ridge, New Jersey  07920
Memorial Sloan-Kettering Cancer Center at CommackCommack, New York  11725
Memorial Sloan-Kettering Cancer Center at Phelps Memorial Hospital CenterSleepy Hollow, New York  10591
Memorial Sloan-Kettering at Mercy Medical CenterRockville Centre, New York